Compare KB Financial Group, Inc. (KB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs GeneDx Holdings Corp — how do they compare? KB Financial Group, Inc. trades at $115.25 (market cap $38.56B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: KB Financial Group, Inc. is far larger — about 21.4× GeneDx Holdings Corp's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KB | WGS | |
|---|---|---|
Market Cap | $38.56B | $1.80B |
Sector | Financials | Technology |
52-Week High | $123.25 | $167.51 |
52-Week Low | $77.50 | $34.51 |
Dividend Yield | 2.72% | — |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB trades at $120.09, up 0.6% with a bullish technical trend and strong earnings momentum, beating estimates for three consecutive quarters. Revenue grew to $21.23T in 2025 with net income margin expanding to 27.82%. The stock shows solid valuation metrics with P/E of 11.07 and P/B of 1.05, while analyst sentiment is mixed with 33% buy ratings amid ongoing diversification into non-banking segments.
The outlook remains positive given consistent earnings beats and ROE expansion potential, though risks include heavy investing cash outflows and reliance on non-banking growth. Institutional hold ratings suggest cautious optimism, with the stock positioned for stability if diversification succeeds but vulnerable to sector volatility.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
